Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | The role of systemic therapy in the context of bladder preservation

Elizabeth R. Plimack • 22 Oct 2023
ESMO 2023
Bladder Cancer

Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, discusses the role of systemic therapies for patients with bladder cancer with the end goal of bladder preservation. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elizabeth R. Plimack

0:52
DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer
Elizabeth R. Plimack • 22 Oct 2023
1:08
The role of molecular biomarkers in determining patient response to bladder cancer treatment
Elizabeth R. Plimack • 22 Oct 2023

Related Videos

1:07
Developing targeted therapies for urachal and non-urachal adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:21
Genomic differences between urachal and non-urachal bladder adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:09
What role does FDG-PET have in managing bladder cancer?
Antonio Cigliola • 26 Jan 2024
1:06
Predicting pelvic lymph node involvement in MIBC with FDG-PET
Antonio Cigliola • 26 Jan 2024
The content of VJOncology is intended for healthcare professionals